OMGAQ (Omega Therapeutics) Change In Receivables: $-0.09 Mil (TTM As of Sep. 2024)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

OMGAQ Omega Therapeutics Inc OMGAQ
16 GF Score
Price $0.00
View Full Analysis

What is Omega Therapeutics Change In Receivables?

Omega Therapeutics OMGAQ +50.00% 16 Change In Receivables is $-0.09 Mil as of Sep. 2024. GuruFocus rates OMGAQ with a GF Score™ of 16/100.

Omega Therapeutics's change in receivables for the quarter that ended in Sep. 2024 was $0.21 Mil. It means Omega Therapeutics's Accounts Receivable declined by $0.21 Mil from Jun. 2024 to Sep. 2024 .

Omega Therapeutics's change in receivables for the fiscal year that ended in Dec. 2023 was $-5.51 Mil. It means Omega Therapeutics's Accounts Receivable increased by $5.51 Mil from Dec. 2022 to Dec. 2023 .

Omega Therapeutics's Accounts Receivable for the quarter that ended in Sep. 2024 was $0.00 Mil.

Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed. Omega Therapeutics's Days Sales Outstanding for the three months ended in Sep. 2024 was 0.00.

In Ben Graham's calculation of liquidation value, Apple Inc's Accounts Receivable are only considered to be worth 75% of book value. Omega Therapeutics's liquidation value for the three months ended in Sep. 2024 was $-110.81 Mil.

Omega Therapeutics  (OTCPK:OMGAQ) Change In Receivables Explanation

1. Accounts Receivable are created when a customer has received a product but has not yet paid for that product. Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed.

Omega Therapeutics's Days Sales Outstanding for the quarter that ended in Sep. 2024 is calculated as:

Days Sales Outstanding
=Accounts Receivable/Revenue*Days in Period
=0/2.612*91
=0.00

2. In Ben Graham's calculation of liquidation value, Omega Therapeutics's accounts receivable are only considered to be worth 75% of book value:

Omega Therapeutics's liquidation value for the quarter that ended in Sep. 2024 is calculated as:

Liquidation Value
=Cash, Cash Equivalents, Marketable Securities-Total Liabilities+(0.75 * Accounts Receivable)+(0.5 * Total Inventories)
=30.377-141.184+0.75 * 0+0.5 * 0
=-110.81

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Omega Therapeutics Change In Receivables Related Terms

Omega Therapeutics Change In Receivables Historical Data

* Premium members only.

The historical data trend for Omega Therapeutics's Change In Receivables can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Omega Therapeutics Change In Receivables Chart

Omega Therapeutics Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23
Change In Receivables
0.00 0.00 -0.26 -0.36 -5.51

Omega Therapeutics Quarterly Data
Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24
Change In Receivables Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.80 -5.73 4.98 0.46 0.21
OMGAQ
16GF Score
Omega Therapeutics Inc OMGAQ
Change In Receivables is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Omega Therapeutics Change In Receivables Calculation

Change In Accounts Receivable relative to the previous period. It is any increase or decrease in the cash a company is owed by its customers.

Change In Receivables for the trailing twelve months (TTM) ended in Sep. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $-0.09 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Change In Receivables →
What does a Change In Receivables of $-0.09 Mil mean?
Omega Therapeutics (OMGAQ) has a Change In Receivables of $-0.09 Mil as of Sep. 2024. Change in Receivables is the difference between current-period receivables and past-period receivables. View historical data for Omega Therapeutics and its competitors.
Is Omega Therapeutics' Change In Receivables too high?
Omega Therapeutics' current Change In Receivables is $-0.09 Mil. Overall, Omega Therapeutics has a GF Score™ of 16/100, reflecting its overall financial health beyond just this single metric.
How does Omega Therapeutics' Change In Receivables compare to ENDV and ORGS?
Omega Therapeutics' Change In Receivables of $-0.09 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Change In Receivables for a Biotechnology company?
A good Change In Receivables depends on the Biotechnology industry context. However, Change In Receivables should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Change In Receivables mean?
A high Change In Receivables can signal that a stock is expensive relative to its fundamentals. Change in Receivables is the difference between current-period receivables and past-period receivables. View historical data for Omega Therapeutics and its competitors. Omega Therapeutics's current Change In Receivables is $-0.09 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Omega Therapeutics stock overvalued right now?
Omega Therapeutics (OMGAQ) has a current Change In Receivables of $-0.09 Mil. The current Change In Receivables is $-0.09 Mil. Omega Therapeutics' overall GF Score™ is 16/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Change In Receivables calculated?
Change In Receivables is calculated from a company's financial statements. For Omega Therapeutics (OMGAQ), the current Change In Receivables is $-0.09 Mil as of Sep. 2024. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Omega Therapeutics Business Description

Address 140 First Street, Suite 501, Cambridge, MA, USA, 02141
Omega Therapeutics Inc is a development-stage biotechnology company leveraging its proprietary epigenomic programming platform to biologically engineer a new class of programmable epigenetic medicines, known as Omega Epigenomic Controllers. Using epigenomic controllers, Omega is seeking to transform the practice of human medicine through selective and direct control of the human genome to treat and cure disease. It operates in the U.S.
16GF Score

Get the complete analysis for OMGAQ

Change In Receivables is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.00
Price